EFFECTS OF STORAGE ON THE BINDING OF CARBOPLATIN TO PLASMA-PROTEINS

被引:32
作者
ERKMEN, K
EGORIN, MJ
REYNO, LM
MORGAN, R
DOROSHOW, JH
机构
[1] UNIV MARYLAND,CTR CANC,DIV DEV THERAPEUT,BALTIMORE,MD 21201
[2] UNIV MARYLAND,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BALTIMORE,MD 21201
[3] CITY HOPE NATL MED CTR,DEPT MED ONCOL & THERAPEUT RES,DUARTE,CA 91010
关键词
CARBOPLATIN; CBDCA; PROTEIN BINDING;
D O I
10.1007/BF00686557
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plasma ultrafiltrates are routinely used in pharmacokinetic studies of carboplatin. Experiments were performed to detect and quantitate artifactual decreases in the platinum concentration of ultrafiltrates prepared from plasma samples stored at -20 degrees C and -70 degrees C. Carboplatin was added to anticoagulated, whole human blood to produce a 20 mu g/ml concentration. Plasma produced from the blood was stored frozen at either -20 degrees C or -70 degrees C. Aliquots from each storage condition were thawed and ultrafiltered once a week for up to 100 days. Platinum concentrations in ultrafiltrates and plasma were determined by flameless atomic absorption spectrometry. There was no loss of ultrafilterable platinum in plasma samples stored at -70 degrees C, whereas there was a steady decrease in free platinum concentration in ultrafiltrates prepared from plasma samples stored at -20 degrees C. These results imply that pharmacokinetic studies of carboplatin should use ultrafiltrates prepared immediately or that plasma for such studies should be stored at -70 degrees C, Storage of carboplatin-containing plasma at -20 degrees C and subsequent ultrafiltration is not acceptable, because measurement of platinum in such ultrafiltrates will be artifactually low.
引用
收藏
页码:254 / 256
页数:3
相关论文
共 22 条
[1]  
BUNN PA, 1990, CARBOPLATIN
[2]   PROGRAM PACKAGE FOR SIMULATION AND PARAMETER-ESTIMATION IN PHARMACOKINETIC SYSTEMS [J].
DARGENIO, DZ ;
SCHUMITZKY, A .
COMPUTER PROGRAMS IN BIOMEDICINE, 1979, 9 (02) :115-134
[3]  
DECONTI RC, 1973, CANCER RES, V33, P3310
[4]  
EGORIN MJ, 1984, CANCER RES, V44, P5432
[5]  
EGORIN MJ, 1985, CANCER RES, V45, P6502
[6]  
GAVER RC, 1987, CANCER CHEMOTH PHARM, V20, P271
[7]  
GHAZALASWAD S, 1991, BRIT J CANCER, V63, P7
[8]  
GONIAS SL, 1983, J BIOL CHEM, V258, P5764
[9]  
GORMLEY PE, 1979, CLIN PHARMACOL THER, V25, P351
[10]   RELATIONSHIPS BETWEEN CARBOPLATIN EXPOSURE AND TUMOR RESPONSE AND TOXICITY IN PATIENTS WITH OVARIAN-CANCER [J].
JODRELL, DI ;
EGORIN, MJ ;
CANETTA, RM ;
LANGENBERG, P ;
GOLDBLOOM, EP ;
BURROUGHS, JN ;
GOODLOW, JL ;
TAN, S ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :520-528